. Author manuscript; available in PMC: 2010 Apr 1.

Published in final edited form as: Eur J Pharmacol. 2009 Apr 1;607(1-3):251–257. doi: 10.1016/j.ejphar.2009.01.042

Table 2.

Hormone concentrations during the basal and experimental periods in conscious 42-h-fasted dogs given saline, or a low or high dose escitalopram infusion into the hepatic portal vein

		Experimental Period
Group	Basal Period	Period 1	Period 2
Arterial Plasma Insulin (pmol/L)
SAL	48±7	116±7^a	130±9^a
L-ESC	48±10	133±12^a	160±13^a
H-ESC	44±3	138±13^a	158±16^a
Hepatic Sinusoidal Insulin (pmol/L)
SAL	132±20	483±78^a	466±63^a
L-ESC	145±45	569±47^a	596±37^a
H-ESC	147±23	571±39^a	589±50^a
Arterial Plasma Glucagon (ng/L)
SAL	43±4	41±3	40±3
L-ESC	40±6	45±9	44±8
H-ESC	35±4	43±3	37±3
Hepatic Sinusoidal Glucagon (ng/L)
SAL	50±4	56±4	53±4
L-ESC	47±5	61±7	57±8
H-ESC	40±4	63±4^a	51±3
Arterial Cortisol (nmol/L)
SAL	109±36	122±21	78±11
L-ESC	88±27	87±23	73±16
H-ESC	100±21	126±16	75±12

Data are mean ± S.E.M.. n=11 dogs in the saline group (SAL), n=6 in the group that received escitalopram at 2 μg/kg/min (L-ESC) and n=7 in the group that received escitalopram at 8 μg/kg/min (H-ESC)

Significant statistical difference (P<0.05) from basal period within the group